Recent clinical trials have demonstrated that semaglutide, the active ingredient in the weight loss drug Wegovy, may effectively treat a serious form of liver disease known as MAFLD (metabolic associated fatty liver disease). Studies indicate that semaglutide can significantly improve liver health, with research revealing that two-thirds of patients experienced noteworthy benefits. The results from the ESSENCE phase 3 trial showcased significant improvements over a 72-week period. This positions semaglutide as a potential solution for many individuals affected by fatty liver disease, suggesting a dual benefit as both a treatment for obesity and a way to combat liver issues.